Therefore, inhibition of HDAC may constitute a novel strategy to disrupt the population of CSC in head and neck tumors, thereby creating a homogeneous population of cancer cells with biologically defined signatures and predictable behavior. The gene discussed is HDAC9; the disease is cancer.